Tags

Type your tag names separated by a space and hit enter

The cost effectiveness of levalbuterol versus racemic albuterol.
Am J Manag Care. 2004 Jul; 10(5 Suppl):S153-7.AJ

Abstract

Albuterol is a selective beta2-agonist that is widely used in the prevention and treatment of reactive airway disease. It is formulated as a racemic mixture containing equal parts of the R- and S-isomers. The therapeutic activity of albuterol is due entirely to the R-isomer, whereas the S-isomer may actually have detrimental effects. Because the slowly metabolized S-isomer tends to accumulate in the body, there has been concern that chronic use of racemic albuterol might lead to loss of effectiveness and clinical deterioration, with potentially serious health and cost consequences. Levalbuterol is a formulation containing only the R-isomer of albuterol, and clinical trials have demonstrated that it offers therapeutic advantages over racemic albuterol. The cost effectiveness of levalbuterol derives mainly from reduced need for acute medical care and hospitalization.

Authors+Show Affiliations

Campion Quinn and Associates LLC.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

15354680

Citation

Quinn, Campion. "The Cost Effectiveness of Levalbuterol Versus Racemic Albuterol." The American Journal of Managed Care, vol. 10, no. 5 Suppl, 2004, pp. S153-7.
Quinn C. The cost effectiveness of levalbuterol versus racemic albuterol. Am J Manag Care. 2004;10(5 Suppl):S153-7.
Quinn, C. (2004). The cost effectiveness of levalbuterol versus racemic albuterol. The American Journal of Managed Care, 10(5 Suppl), S153-7.
Quinn C. The Cost Effectiveness of Levalbuterol Versus Racemic Albuterol. Am J Manag Care. 2004;10(5 Suppl):S153-7. PubMed PMID: 15354680.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cost effectiveness of levalbuterol versus racemic albuterol. A1 - Quinn,Campion, PY - 2004/9/10/pubmed PY - 2004/10/13/medline PY - 2004/9/10/entrez SP - S153 EP - 7 JF - The American journal of managed care JO - Am J Manag Care VL - 10 IS - 5 Suppl N2 - Albuterol is a selective beta2-agonist that is widely used in the prevention and treatment of reactive airway disease. It is formulated as a racemic mixture containing equal parts of the R- and S-isomers. The therapeutic activity of albuterol is due entirely to the R-isomer, whereas the S-isomer may actually have detrimental effects. Because the slowly metabolized S-isomer tends to accumulate in the body, there has been concern that chronic use of racemic albuterol might lead to loss of effectiveness and clinical deterioration, with potentially serious health and cost consequences. Levalbuterol is a formulation containing only the R-isomer of albuterol, and clinical trials have demonstrated that it offers therapeutic advantages over racemic albuterol. The cost effectiveness of levalbuterol derives mainly from reduced need for acute medical care and hospitalization. SN - 1088-0224 UR - https://www.unboundmedicine.com/medline/citation/15354680/The_cost_effectiveness_of_levalbuterol_versus_racemic_albuterol_ L2 - https://www.ajmc.com/pubMed.php?pii=2637 DB - PRIME DP - Unbound Medicine ER -